The Pierre Fabre-backed antibody therapy developer has closed a series A round featuring new and founding investors.
Pharmaceutical and cosmetics producer Pierre Fabre has acquired a stake in US-based autoimmune and inflammatory drug developer ValenzaBio in connection with a $70m series A round for the latter. Investment and financial services group Fidelity Management & Research, Surveyor Capital, Ikarian Capital, Janus Henderson Investors and Opaleye Management supplied the series A funds while Pierre…
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.